Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Recruiting · NCT06333899 · Registry updated 2026-06-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, anaplastic astrocytoma, astrocytoma (excluding glioblastoma), brain disorder, brainstem cancer, central nervous system cancer, central nervous system disorder, diffuse intrinsic pontine glioma, epithelial neoplasm, glioblastoma, glioma, grade III glioma, malignant glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Early phase 1 | 2026-06-29 | NCT06333899 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nationwide Children's Hospital | 97 |
| Pfizer | 431 |
18 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.